Screening iLCT-evaluated drugs
This preclinical study will compare the effectiveness of 100 drugs previously evaluated by our iLCT committee to better prioritise the most promising compounds for clinical trial. Contents About the study Prof Heather Mortiboys at the University of Sheffield will be conducting a two-year pre-clinical study...
DAPA-PD: Dapansutrile for Parkinson’s
DAPA-PD is a phase 2 clinical trial of dapansutrile – a novel anti-inflammatory drug – to determine whether it may be able to slow Parkinson’s progression. Contents About the study Led by Dr Caroline Williams-Gray at Cambridge University, DAPA-PD will recruit 36 people with Parkinson’s....
iLCT Pipeline Project: Probucol and chlorogenic acid
This preclinical study aims to gather evidence on whether two compounds – probucol and chlorogenic acid – have a neuroprotective effect in models of Parkinson’s. Contents About the study Both probucol and chlorogenic acid have been evaluated by the International Linked Clinical Trials (iLCT) committee,...
Exenatide-PD3: Exenatide and Parkinson’s
The Exenatide-PD3 study was a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon) which finished in early 2024. The results of this trial have now been published and they indicate that the study did not slow the progression of Parkinson’s compared to...
ASPro-PD: Ambroxol and Parkinson’s
ASPro-PD, or Ambroxol to Slow Progression in Parkinson’s, is a phase 3 clinical trial looking to assess whether ambroxol, a cough medicine, can slow or stop the progression of Parkinson’s motor symptoms. Contents About the study Led by Professor Anthony Schapira at University College London...
The UP Study: UDCA and Parkinson’s
The UP Study, or UDCA for Parkinson’s Study, was a phase 2 clinical trial which aimed to assess the safety and tolerability of ursodeoxycholic acid (UDCA) in people with Parkinson’s. Contents About the study Led by Professor Oliver Bandmann at the University of Sheffield, this...